Rhythm Pharmaceuticals Inc (RYTM)

$90.52 -3.11 (-3.32%)
Market Cap 6.42B
Revenue (ttm) 189.76M
Net Income (ttm) -196.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.57%
Debt to Equity Ratio 0.00
Volume 576,700
Avg Vol 876,456
Day's Range N/A - N/A
Shares Out 68.53M
Stochastic %K 31%
Beta 1.94
Analysts Strong Sell
Price Target $138.13

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
SuperGreenToday
SuperGreenToday May. 14 at 10:39 PM
$RYTM Share Price: $93.60 Contract Selected: Oct 16, 2026 $95 Calls Buy Zone: $11.90 – $14.70 Target Zone: $19.79 – $24.19 Potential Upside: 57% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TeeMan123
TeeMan123 May. 14 at 2:20 PM
$RYTM GIVE US BUYOUT CHATTER!!!
0 · Reply
SportTrade
SportTrade May. 14 at 1:54 PM
$PTN $RYTM This was a positive update in my opinion making Palatin even more desirable as an acquisition target which is my investment thesis… here’s why: Palatin’s pivot to advancing a highly selective, next-generation MC4R agonist directly addresses the primary clinical shortcomings—such as daily dosing and hyperpigmentation—of current first-generation therapies. By prioritizing a "best-in-class" profile with weekly injections and oral delivery, they are positioning their pipeline as an essential life-cycle management tool for incumbent (RYTM) or an entry point for Big Pharma. The investment thesis for a micro-cap biotech like Palatin is not the high-risk, high-cost path of independent commercialization, but rather creation of a de-risked, superior asset that acts as a strategic "must-have." IMO their value thus SP upside lies in being a turnkey acquisition target, offering BP a reinforced moat and a clear path to market dominance in the multi-billion dollar rare obesity space.
0 · Reply
Hognose
Hognose May. 13 at 10:12 PM
$RYTM clown show here
0 · Reply
Dkll303
Dkll303 May. 11 at 8:39 PM
$RYTM John Maraganore, has him beat !!!
0 · Reply
Hognose
Hognose May. 11 at 4:28 PM
$RYTM all run ups get sold.
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface May. 11 at 4:27 PM
$RYTM Meeker, sell the company now unless you’re holding out for $61. (Not a typo)
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 8 at 2:07 AM
$RYTM RSI: 65.38, MACD: 1.0471 Vol: 4.14, MA20: 86.86, MA50: 87.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
abcdzepeda
abcdzepeda May. 7 at 3:00 AM
$RYTM I could be wrong, but I think we’re finally turning the corner towards a more bullish trend! 
0 · Reply
Hognose
Hognose May. 5 at 7:28 PM
$RYTM this thing can't hold any gains.
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 6:00 PM EDT - 2 days ago

Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

May 12, 2026, 8:00 AM EDT - 3 days ago

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord

2026-05-07T16:30:44.000Z - 8 days ago

Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

May 6, 2026, 8:00 AM EDT - 9 days ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 10 days ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026

Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)

2026-05-05T11:34:07.000Z - 10 days ago

Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)

Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M

2026-05-05T11:32:44.000Z - 10 days ago

Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 5, 2026, 7:00 AM EDT - 10 days ago

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

2026-05-04T13:38:56.000Z - 11 days ago

Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

May 4, 2026, 8:00 AM EDT - 11 days ago

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity

2026-05-01T11:26:03.000Z - 14 days ago

Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

May 1, 2026, 6:55 AM EDT - 14 days ago

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 11:00 AM EDT - 4 weeks ago

Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Apr 9, 2026, 8:00 AM EDT - 5 weeks ago

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Rhythm Pharmaceuticals price target raised to $136 from $130 at RBC Capital

2026-04-07T15:04:23.000Z - 5 weeks ago

Rhythm Pharmaceuticals price target raised to $136 from $130 at RBC Capital

Rhythm Pharmaceuticals appoints Popovits to board of directors

2026-04-06T01:15:43.000Z - 5 weeks ago

Rhythm Pharmaceuticals appoints Popovits to board of directors

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Apr 3, 2026, 9:00 AM EDT - 6 weeks ago

Rhythm Pharmaceuticals Announces Changes to Board of Directors

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Mar 26, 2026, 9:01 AM EDT - 7 weeks ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright

2026-03-23T10:11:20.000Z - 7 weeks ago

Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright

Rhythm Pharmaceuticals selects Pantherx Rare as pharmacy for Imcivree

2026-03-20T17:15:33.000Z - 2 months ago

Rhythm Pharmaceuticals selects Pantherx Rare as pharmacy for Imcivree

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Mar 20, 2026, 12:58 PM EDT - 2 months ago

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA

2026-03-20T13:36:25.000Z - 2 months ago

Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA

Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi

2026-03-20T10:26:31.000Z - 2 months ago

Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi

Rhythm Pharmaceuticals price target raised to $155 from $152 at Citizens

2026-03-20T09:40:15.000Z - 2 months ago

Rhythm Pharmaceuticals price target raised to $155 from $152 at Citizens

Rhythm Pharmaceuticals trading resumes

2026-03-19T23:05:19.000Z - 2 months ago

Rhythm Pharmaceuticals trading resumes

Rhythm Pharmaceuticals Transcript: Study update

Mar 19, 2026, 7:00 PM EDT - 2 months ago

Rhythm Pharmaceuticals Transcript: Study update

Rhythm Pharmaceuticals trading halted, news pending

2026-03-19T22:30:39.000Z - 2 months ago

Rhythm Pharmaceuticals trading halted, news pending

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Mar 19, 2026, 6:30 PM EDT - 2 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm price target lowered to $100 from $110 at H.C. Wainwright

2026-03-18T10:11:05.000Z - 2 months ago

Rhythm price target lowered to $100 from $110 at H.C. Wainwright

Rhythm Pharmaceuticals price target lowered to $130 from $140 at RBC Capital

2026-03-17T11:28:30.000Z - 2 months ago

Rhythm Pharmaceuticals price target lowered to $130 from $140 at RBC Capital

Rhythm Pharmaceuticals price target lowered to $139 from $145 at BofA

2026-03-17T10:30:15.000Z - 2 months ago

Rhythm Pharmaceuticals price target lowered to $139 from $145 at BofA

Rhythm Pharmaceuticals price target lowered to $136 from $150 at Morgan Stanley

2026-03-17T10:21:03.000Z - 2 months ago

Rhythm Pharmaceuticals price target lowered to $136 from $150 at Morgan Stanley

Rhythm Pharmaceuticals price target lowered to $131 from $136 at Citi

2026-03-17T09:50:54.000Z - 2 months ago

Rhythm Pharmaceuticals price target lowered to $131 from $136 at Citi

Rhythm Pharmaceuticals Transcript: Study result

Mar 16, 2026, 4:30 PM EDT - 2 months ago

Rhythm Pharmaceuticals Transcript: Study result

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Mar 16, 2026, 4:07 PM EDT - 2 months ago

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Mar 16, 2026, 4:01 PM EDT - 2 months ago

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Rhythm Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:10 AM EST - 2 months ago

Rhythm Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Mar 1, 2026, 12:30 PM EST - 2 months ago

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q4 2025

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 26, 2026, 7:00 AM EST - 2 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

Feb 17, 2026, 8:00 AM EST - 3 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

Rhythm Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 11:00 AM EST - 3 months ago

Rhythm Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

Feb 5, 2026, 8:00 AM EST - 3 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Jan 9, 2026, 8:00 AM EST - 4 months ago

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Rhythm Pharmaceuticals Transcript: Study Result

Dec 11, 2025, 8:00 AM EST - 5 months ago

Rhythm Pharmaceuticals Transcript: Study Result

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Dec 11, 2025, 7:30 AM EST - 5 months ago

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Dec 10, 2025, 4:01 PM EST - 5 months ago

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Rhythm Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 9:30 AM EST - 6 months ago

Rhythm Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Nov 7, 2025, 7:30 AM EST - 6 months ago

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Nov 5, 2025, 4:01 PM EST - 6 months ago

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Rhythm Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 6 months ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q3 2025

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Nov 4, 2025, 7:00 AM EST - 6 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 4:01 PM EDT - 7 months ago

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Rhythm Pharmaceuticals Transcript: Status Update

Sep 24, 2025, 8:30 AM EDT - 8 months ago

Rhythm Pharmaceuticals Transcript: Status Update

Rhythm Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 11:30 AM EDT - 8 months ago

Rhythm Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Rhythm Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 9:30 AM EDT - 9 months ago

Rhythm Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Aug 20, 2025, 4:01 PM EDT - 9 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2025

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Jul 22, 2025, 4:01 PM EDT - 10 months ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 12, 2025, 6:00 PM EDT - 10 months ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 10, 2025, 6:21 AM EDT - 11 months ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 11 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Transcript: Study Result

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Transcript: Study Result

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 11 months ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Jun 25, 2025, 8:00 AM EDT - 11 months ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Rhythm Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Rhythm Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Rhythm Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Rhythm Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 12:20 PM EDT - 1 year ago

Rhythm Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 14, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2025

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 7, 2025, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Rhythm Pharmaceuticals Transcript: Study Result

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Transcript: Study Result

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:11 AM EDT - 1 year ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 1 year ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 1 year ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Rhythm Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q4 2024

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 26, 2025, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Feb 13, 2025, 8:00 AM EST - 1 year ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Rhythm Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 8:40 AM EST - 1 year ago

Rhythm Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Jan 10, 2025, 7:15 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 20, 2024, 2:15 PM EST - 1 year ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

Rhythm Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 18, 2024, 7:00 AM EST - 1 year ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

SuperGreenToday
SuperGreenToday May. 14 at 10:39 PM
$RYTM Share Price: $93.60 Contract Selected: Oct 16, 2026 $95 Calls Buy Zone: $11.90 – $14.70 Target Zone: $19.79 – $24.19 Potential Upside: 57% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TeeMan123
TeeMan123 May. 14 at 2:20 PM
$RYTM GIVE US BUYOUT CHATTER!!!
0 · Reply
SportTrade
SportTrade May. 14 at 1:54 PM
$PTN $RYTM This was a positive update in my opinion making Palatin even more desirable as an acquisition target which is my investment thesis… here’s why: Palatin’s pivot to advancing a highly selective, next-generation MC4R agonist directly addresses the primary clinical shortcomings—such as daily dosing and hyperpigmentation—of current first-generation therapies. By prioritizing a "best-in-class" profile with weekly injections and oral delivery, they are positioning their pipeline as an essential life-cycle management tool for incumbent (RYTM) or an entry point for Big Pharma. The investment thesis for a micro-cap biotech like Palatin is not the high-risk, high-cost path of independent commercialization, but rather creation of a de-risked, superior asset that acts as a strategic "must-have." IMO their value thus SP upside lies in being a turnkey acquisition target, offering BP a reinforced moat and a clear path to market dominance in the multi-billion dollar rare obesity space.
0 · Reply
Hognose
Hognose May. 13 at 10:12 PM
$RYTM clown show here
0 · Reply
Dkll303
Dkll303 May. 11 at 8:39 PM
$RYTM John Maraganore, has him beat !!!
0 · Reply
Hognose
Hognose May. 11 at 4:28 PM
$RYTM all run ups get sold.
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface May. 11 at 4:27 PM
$RYTM Meeker, sell the company now unless you’re holding out for $61. (Not a typo)
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 8 at 2:07 AM
$RYTM RSI: 65.38, MACD: 1.0471 Vol: 4.14, MA20: 86.86, MA50: 87.57 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
abcdzepeda
abcdzepeda May. 7 at 3:00 AM
$RYTM I could be wrong, but I think we’re finally turning the corner towards a more bullish trend! 
0 · Reply
Hognose
Hognose May. 5 at 7:28 PM
$RYTM this thing can't hold any gains.
0 · Reply
TeeMan123
TeeMan123 May. 5 at 4:52 PM
$RYTM the godfather of rare diseases David Meeker strikes again… what an insanely great launch >150 start forms!! Meeker aged 71 sitting on $350MM worth of stock at current valiations. Dude is going to sell this company and retire as storied biotech CEO!!!! Let’s go!!! 🚀🚀
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 11:53 AM
$RYTM Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.83 down -2.47% YoY • Reported revenue of $60.11M up 83.81% YoY • For the year ending December 31, 2026, Rhythm Pharmaceuticals expects Non-GAAP Operating Expenses to range from approximately $385M to $415M, reflecting ongoing operational investments.
0 · Reply
Hognose
Hognose May. 2 at 6:40 PM
$RYTM getting close to that 78 buy area.
2 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 11:34 PM
$RYTM Current Stock Price: $81.78 Contracts to trade: $80.0 RYTM May 15 2026 Call Entry: $4.90 Exit: $6.97 ROI: 42% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Dkll303
Dkll303 Apr. 28 at 12:07 PM
$CADL …truth , shall set you free !!! When you admit , you know NOTHING about SEC regulations, 10-B , Rule 144A , quiet periods . Someday , you’ll learn who and what criteria a Board member must meet to be on the Board !!! Until then, you are marked at $CADL and $RYTM , lol Happy day
0 · Reply
Dkll303
Dkll303 Apr. 28 at 10:36 AM
$RYTM @Reneejordan001 found a likely sympathetic soul to give support to those without knowledge of big money, and who’s who in company dynamics !!! Meet your new uninformed supporter @Stonky_Mcprofitface , There are circles to be connected with, clearly neither of you are in them , lol …stick with your audience at StockTwits !!!
1 · Reply
Dkll303
Dkll303 Apr. 28 at 10:31 AM
$RYTM clearly ,you are just a retail hack, knowing nothing about companies and board members ! Dafuq is this dolt , without a brain @Stonky_Mcprofitface …ID’ed , lol
0 · Reply
Dkll303
Dkll303 Apr. 28 at 10:29 AM
$RYTM oh ! Add $CADL , $QURE , $AGIO , the biggest fcuk up of the group ! FOUSE/GOFF
0 · Reply
Hognose
Hognose Apr. 28 at 8:51 AM
$CAPR $NUVL $ASND $RYTM $ABVX monsters in the making.
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 24 at 1:45 PM
$RYTM Absolute dog
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 23 at 2:45 PM
$RYTM Very low volume today
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Apr. 23 at 11:37 AM
$RYTM dafuq is this idiot chimpin on about?
1 · Reply